{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:04:58Z","timestamp":1767855898532,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Patients with non-ischaemic cardiomyopathy (NICMP) have a\u00a0class\u00a0IIa primary prevention indication for an implantable cardioverter-defibrillator (ICD). Recent studies have shown that the evidence for a\u00a0survival benefit following ICD implantation in this patient group is not particularly robust. In 2023, the Dutch Society of Cardiology published an update of the ESC guideline to better select patients with NICMP for ICD implantation. The objective of this study was to analyse the impact of this guideline on the number of indications in a\u00a0retrospective cohort of patients who had received an ICD and whether the patients without an indication were also without appropriate ICD therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A\u00a0single-centre, retrospective observational study was performed in 134 patients with NICMP who underwent ICD implantation for primary prevention between 2015 and 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:italic>Results<\/jats:italic>\n            <\/jats:title>\n            <jats:p>After applying the new Dutch guideline, 74\u00a0out of 134 patients with NICMP without a\u00a0high-risk phenotype (35\u00a0patients) had no ICD indication (group\u00a02). The remaining 25\u00a0patients were considered to have an ICD indication (group\u00a01). During a\u00a0median follow-up of 66\u00a0months (interquartile range 52\u201381) the incidence of appropriate ICD therapy (antitachycardia pacing and shock) was comparable in both groups: 4\u00a0patients in group\u00a01 (16%) and 9\u00a0in group\u00a02 (12%), <jats:italic>p<\/jats:italic>\u202f=\u20090.623.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:italic>Conclusion<\/jats:italic>\n            <\/jats:title>\n            <jats:p>The new 2023 guideline for ICD implantation in NICMP patients does indeed rule out a\u00a0significant group of patients from ICD implantation. Nevertheless, our data show that patients without an indication still had comparable rates of appropriate ICD therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12471-025-01960-5","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T08:49:11Z","timestamp":1747039751000},"page":"186-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Primary prevention ICD in non-ischaemic cardiomyopathy: an ongoing search for improvement of current indications"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-3098","authenticated-orcid":false,"given":"Reinder","family":"Evertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rypko","family":"Beukema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd","family":"Westra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Nijveldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Vernooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"1960_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M, et\u00a0al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1960_CR2","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld\u00a0K, Tfelt-Hansen\u00a0J, de Riva\u00a0M, et\u00a0al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart\u00a0J. 2022;43:3997\u20134126.","journal-title":"Eur Heart J"},{"key":"1960_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","volume":"105","author":"D Bansch","year":"2002","unstructured":"Bansch\u00a0D, Antz\u00a0M, Boczor\u00a0S, et\u00a0al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT). Circulation. 2002;105:1453\u20138.","journal-title":"Circulation"},{"key":"1960_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy\u00a0GH, Lee\u00a0KL, Mark\u00a0DB, et\u00a0al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N\u00a0Engl J Med. 2005;352:225\u201337.","journal-title":"N Engl J Med"},{"key":"1960_CR5","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa033088","volume":"350","author":"A Kadish","year":"2004","unstructured":"Kadish\u00a0A, Dyer\u00a0A, Daubert\u00a0JP, et\u00a0al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N\u00a0Engl J Med. 2004;350:2151\u20138.","journal-title":"N Engl J Med"},{"key":"1960_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","volume":"375","author":"L K\u00f8ber","year":"2016","unstructured":"K\u00f8ber\u00a0L, Thune\u00a0JJ, Nielsen\u00a0JC, et\u00a0al. Defibrillator implantation in patients with nonischemic systolic heart failure. N\u00a0Engl J Med. 2016;375:1221\u201330.","journal-title":"N Engl J Med"},{"key":"1960_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0735-1097(03)00297-3","volume":"41","author":"SA Strickberger","year":"2003","unstructured":"Strickberger\u00a0SA, Hummel\u00a0JD, Bartlett\u00a0TG, et\u00a0al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia\u2014AMIOVIRT. J\u00a0Am Coll Cardiol. 2003;41:1707\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"1960_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12471-022-01718-3","volume":"31","author":"DA Theuns","year":"2023","unstructured":"Theuns\u00a0DA, Verstraelen\u00a0TE, van der Lingen\u00a0ACJ, et\u00a0al. Implantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy: an updated meta-analysis and effect on Dutch clinical practice by the Task Force of the Dutch Society of Cardiology. Neth Heart\u00a0J. 2023;31:89\u201399.","journal-title":"Neth Heart J"},{"key":"1960_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray\u00a0JJ, Packer\u00a0M, Desai\u00a0AS, et\u00a0al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"1960_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE, et\u00a0al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1960_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J, et\u00a0al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N\u00a0Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1960_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad\u00a0F, Ferreira\u00a0JP, Pocock\u00a0SJ, et\u00a0al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a\u00a0meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819\u201329.","journal-title":"Lancet"},{"key":"1960_CR13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jcmg.2018.03.006","volume":"11","author":"MAJ Becker","year":"2018","unstructured":"Becker\u00a0MAJ, Cornel\u00a0JH, van de Ven\u00a0PM, van Rossum\u00a0AC, Allaart\u00a0CP, Germans\u00a0T. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a\u00a0review and meta-analysis. JACC Cardiovasc Imaging. 2018;11:1274\u201384.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1960_CR14","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/CIRCULATIONAHA.116.026910","volume":"135","author":"BP Halliday","year":"2017","unstructured":"Halliday\u00a0BP, Gulati\u00a0A, Ali\u00a0A, Guha\u00a0K, et\u00a0al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135:2106\u201315.","journal-title":"Circulation"},{"key":"1960_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/CIRCULATIONAHA.120.048477","volume":"143","author":"I Klem","year":"2021","unstructured":"Klem\u00a0I, Klein\u00a0M, Khan\u00a0M, Yang\u00a0EY, et\u00a0al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation. 2021;143:1343\u201358.","journal-title":"Circulation"},{"key":"1960_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/heartjnl-2016-310850","volume":"104","author":"SAS Beggs","year":"2018","unstructured":"Beggs\u00a0SAS, Jhund\u00a0PS, Jackson\u00a0CE, McMurray\u00a0JJV, Gardner\u00a0RS. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a\u00a0review and meta-analysis. Heart. 2018;104:144\u201350.","journal-title":"Heart"},{"key":"1960_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/jce.12767","volume":"26","author":"M Chimura","year":"2015","unstructured":"Chimura\u00a0M, Kiuchi\u00a0K, Okajima\u00a0K, et\u00a0al. Distribution of ventricular fibrosis associated with life-threatening ventricular tachyarrhythmias in patients with nonischemic dilated cardiomyopathy. J\u00a0Cardiovasc Electrophysiol. 2015;26:1239\u201346.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1960_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/eurheartj\/ehy437","volume":"40","author":"SJ Gutman","year":"2019","unstructured":"Gutman\u00a0SJ, Costello\u00a0BT, Papapostolou\u00a0S, et\u00a0al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart\u00a0J. 2019;40:542\u201350.","journal-title":"Eur Heart J"},{"key":"1960_CR19","unstructured":"NVVC. Indicatierichtlijn primaire preventie ICD plaatsing bij NICM. 2023; www.nvvc.nl\/richtlijnen"},{"key":"1960_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.cardfail.2017.11.002","volume":"24","author":"AC Alba","year":"2018","unstructured":"Alba\u00a0AC, Walter\u00a0SD, Guyatt\u00a0GH, et\u00a0al. Predicting survival in patients with heart failure with an implantable cardioverter defibrillator: the Heart Failure Meta-score. J\u00a0Card Fail. 2018;24:735\u201345.","journal-title":"J Card Fail"},{"key":"1960_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2021.01.011","volume":"330","author":"D Theuns","year":"2021","unstructured":"Theuns\u00a0D, Schaer\u00a0BA, Caliskan\u00a0K, et\u00a0al. Application of the heart failure meta-score to predict prognosis in patients with cardiac resynchronization defibrillators. Int J Cardiol. 2021;330:73\u20139.","journal-title":"Int J Cardiol"},{"key":"1960_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/europace\/euab012","volume":"31","author":"TM Verstraelen","year":"2021","unstructured":"Verstraelen\u00a0TM, van Barreveld\u00a0M, van Dessel\u00a0PHFM, et\u00a0al. Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace. 2021;31:887\u201397.","journal-title":"Europace"},{"key":"1960_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12471-023-01785-0","volume":"31","author":"R Evertz","year":"2023","unstructured":"Evertz\u00a0R, van der Heijden\u00a0T, Beukema\u00a0R, et\u00a0al. Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention. Neth Heart\u00a0J. 2023;31:348\u201356.","journal-title":"Neth Heart J"},{"key":"1960_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1056\/NEJMoa1915932","volume":"383","author":"R Knops","year":"2020","unstructured":"Knops\u00a0R, Nordkamp\u00a0OLRA, Delnoy\u00a0PHM, et\u00a0al. Subcutaneous or transvenous defibrillator therapy. N\u00a0Engl J Med. 2020;383:526\u201336.","journal-title":"N Engl J Med"},{"key":"1960_CR25","doi-asserted-by":"publisher","first-page":"e018063","DOI":"10.1161\/JAHA.120.018063","volume":"10","author":"M van Barreveld","year":"2021","unstructured":"van Barreveld\u00a0M, Verstraelen\u00a0TE, van Dessel\u00a0P, et\u00a0al. Dutch outcome in implantable cardioverter-defibrillator therapy: implantable cardioverter-defibrillator-related complications in a\u00a0contemporary primary prevention cohort. J\u00a0Am Heart Assoc. 2021;10:e18063.","journal-title":"J Am Heart Assoc"},{"key":"1960_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12471-024-01859-7","volume":"32","author":"ACJ van der Lingen","year":"2024","unstructured":"van der Lingen\u00a0ACJ, Verstraelen\u00a0TE, van Erven\u00a0L, et\u00a0al. Assessment of ICD eligibility in non-ischaemic cardiomyopathy patients: a\u00a0position statement by the Task Force of the Dutch Society of Cardiology. Neth Heart\u00a0J. 2024;32:190\u20137.","journal-title":"Neth Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01960-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-025-01960-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01960-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:17:48Z","timestamp":1747912668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-025-01960-5"}},"subtitle":["A retrospective study analysing the impact of the new Dutch guideline on the use of ICDs"],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1960"],"URL":"https:\/\/doi.org\/10.1007\/s12471-025-01960-5","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"14 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.\u00a0Vernooy and R.\u00a0Nijveldt are Associate Editors of the Netherlands Heart Journal. R.\u00a0Evertz, R.\u00a0Beukema and S.\u00a0Westra declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}